Analyst Skorney and Wells Fargo Maintain a Buy Rating for Soleno Therapeutics

Summary

Analyst Skorney and Wells Fargo have maintained a Buy rating on Soleno Therapeutics, with price targets suggesting nearly 100% upside from current levels.Tip Ranks

Impact Analysis

So basically, both Skorney and Wells Fargo are doubling down on Soleno Therapeutics with buy ratings and ambitious price targets—$119.60 and $123.00, respectively, indicating a near 100% upside from current levels Tip Ranks. The interesting part isn’t just the bullish stance, but the context: Skorney’s average return is -7.5% with a 36.33% success rate, which might make some investors skeptical about the reliability of this call Tip Ranks. However, the consensus remains a ‘Strong Buy,’ suggesting broader market optimism. The market might be missing the potential execution risks or overestimating the company’s ability to meet these high expectations. If the technical indicators are indeed bullish as suggested, this could be a high-risk, high-reward play Cointelegraph. I’d read this as a speculative opportunity, but one that requires careful monitoring of upcoming catalysts and financial health to ensure the thesis holds.